Seres Therapeutics, INC

Seres Therapeutics stockholders approved an amendment to the 2025 Incentive Award Plan, increasing available shares, and ratified auditor appointment at the reconvened annual meeting.

Seres Therapeutics announced encouraging top-line results from an investigator-sponsored trial evaluating SER-155 in patients with immune checkpoint inhibitor-related enterocolitis (irEC).

Seres Therapeutics has amended its Nestlé asset purchase agreement and restructured its office lease to extend its cash runway into Q1 2027.

Seres Therapeutics, Inc. announced the resignation of Dr. Hans-Juergen Woerle from its board of directors, effective May 31, 2026.

Seres Therapeutics reported Q1 2026 financial results, highlighting upcoming clinical readouts for SER-155 and advancing its I&I pipeline, while managing operational expenses and seeking capital.

Seres Therapeutics, Inc. announced the date for its 2026 annual meeting of stockholders and a revised deadline for stockholder proposals.

Seres Therapeutics filed its Q1 2026 Form 10-Q, detailing a net loss of $19.9 million and highlighting ongoing efforts to secure additional funding while pausing investment in the SER-155 Phase 2 study.

Seres Therapeutics reports Q3 2025 net income driven by VOWST sale proceeds, but faces substantial doubt about its ability to continue as a going concern beyond Q2 2026 without additional funding.

Seres Therapeutics reported a net income for the first half of 2025 driven by the VOWST business sale, but faces substantial doubt about its ability to continue as a going concern without additional funding by Q1 2026.

Seres Therapeutics reports a net income of $32.7 million for Q1 2025, driven by the sale of its VOWST business, while focusing on the development of SER-155 and seeking strategic partnerships.

Seres Therapeutics finalized the sale of its VOWST business to Nestl Health Science, shifting its focus to advancing its pipeline, particularly SER-155.

Seres Therapeutics has agreed to sell its VOWST business to Nestl for up to $335 million plus future royalties, while also reporting a net loss of $73 million for the first half of 2024 and raising concerns about its ability to continue as a going concern.

Seres Therapeutics, Inc. reports a strategic pivot towards inflammatory and immune diseases, pausing further investment in its lead infectious disease candidate SER-155's Phase 2 study due to funding needs, while detailing 2025 financial results including a net income from continuing operations.

Seres Therapeutics details its financial position and strategic shift following the sale of its VOWST business, emphasizing the development of SER-155 and other live biotherapeutic candidates.

Seres Therapeutics details its capital stock, reports a net loss of $113.7 million for 2023, and outlines strategic restructuring efforts.

Kurt Graves, a Director at Seres Therapeutics, Inc., acquired stock options for 6,500 shares of common stock.

Richard N. Kender, Director and Officer at Seres Therapeutics, acquired 50,000 stock options with an exercise price of $9.13.

Matthew R. Henn, President and Chief Scientific Officer of Seres Therapeutics, Inc., was granted 25,000 stock options with an exercise price of $9.13.

Marella Thorell, EVP and Chief Financial Officer of Seres Therapeutics, Inc., acquired 7,500 stock options.

Claire Fraser, a Director at Seres Therapeutics, Inc., reported the acquisition of stock options.

Willard H. Dere, a Director at Seres Therapeutics, Inc., acquired stock options for 6,500 shares of common stock.

Seres Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 9th, to address key corporate matters including director elections and equity plan amendments.

Seres Therapeutics files a supplement to its proxy statement to correct an error in the calculation of total shareholder return (TSR) within the Executive Compensation section.

Seres Therapeutics is asking stockholders to approve a reverse stock split, an amended incentive award plan, and other corporate governance changes at its upcoming annual meeting.

Seres Therapeutics announces positive topline results from its SER-155 Phase 1b study, demonstrating a significant reduction in bloodstream infections and antibiotic use in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Seres Therapeutics is selling its VOWST microbiome therapeutic business to Socit des Produits Nestl S.A. for an upfront payment and potential milestone payments, plus a profit share period.

Seres Therapeutics discussed the sale of Vowst to Nestl, the upcoming SER-155 data readout, and the potential of its microbiome therapeutics platform at the Canaccord Genuity Growth Conference.

FMR LLC and Abigail P. Johnson have filed an Amendment No. 14 to Schedule 13G, reporting a beneficial ownership of 3.1% in Seres Therapeutics Inc. common stock as of June 30, 2025.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have filed an amended Schedule 13G, reporting a 5.7% beneficial ownership stake in Seres Therapeutics Inc. as of May 30, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, confirming their beneficial ownership of 12.8% of Seres Therapeutics Inc.'s common stock as of December 31, 2024.